Multiple myeloma is a type of cancer that begins in plasma cells — cells in the bone marrow, that, under normal circumstances, are involved in our immune defense system and produce antibodies. In multiple myeloma, too many plasma cells (myeloma cells) build up in the bone marrow. The presence of these tumor cells in the … Read more
With new research in immunotherapy and targeted therapy, treatment options for blood cancer patients are rapidly expanding. Combination therapies have also caused much excitement among researchers and physicians, and ongoing clinical trials are continuing to look at new strategies that use multiple drugs for fighting these diseases. In this Cancer Conversations podcast episode, Irene Ghobrial, … Read more
The last two years have been very exciting for blood cancer research; many new targeted therapies and immunotherapies are improving treatment outcomes for patients with lymphoma, leukemia and multiple myeloma. “We’re starting to see a lot of hematologic malignancies benefit from immunotherapy,” says Irene Ghobrial, MD. “The excitement is there for so many trials and … Read more
By Elise Renner There’s a 1-in-12 chance that this is the month yours or your loved one’s cancer is recognized—odds better than the survival rates for some of these diseases. Some months, like October, boast big names like breast cancer. Others, like September, are crowded with lesser-known branches of the disease. “Cancer apparel,” including ribbons … Read more
By Ethan Hawes “Having cancer in college doesn’t seem real.” That was my first thought when I received what would become life-changing news at the age of 22 as a senior at the University of Maine (Orono). My body went numb and tears started to form when my doctor told me I had multiple myeloma, … Read more
Multiple myeloma is one of the most compelling examples of a cancer in which research has markedly improved the length and quality of patients’ lives in the last decade. A malignancy of certain white blood cells in the bone marrow known as plasma cells, myeloma is still considered incurable, but treatment advances have significantly improved survival. … Read more
Not long ago, a diagnosis of multiple myeloma — a cancer of the bone marrow — carried with it a very poor prognosis, with median survival estimates of just two to three years. Now, thanks in large part to research and treatment advances at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), this disease is for many … Read more
NBC News’ Tom Brokaw, 74, revealed this week he has multiple myeloma, a cancer of the bone marrow. The disease, also known as plasma cell myeloma, will be diagnosed in more than 24,000 Americans this year.
The 21st century has seen great strides in treatment for multiple myeloma, a cancer of the bone marrow once considered a death sentence. In fact, thanks to research by Dana-Farber scientists, this blood cancer that took the lives of Geraldine Ferraro and Leonard P. Zakim has become a chronic disease for many patients.
In most ways, Bill Ross’s stem cell transplant for multiple myeloma at Dana-Farber Brigham Cancer Center (DFBCC) wasn’t out of the ordinary. He received chemotherapy to destroy the tumor cells in his body and then an infusion of his own hematopoietic stem cells, which flocked to his bone marrow and regenerated his blood supply. Over … Read more
Results of several phase 3 trials and dozens of other studies led by Dana-Farber researchers were presented online and in person June 3-7 at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting. Some of the research reports presented by Dana-Farber investigators include: Improved progression-free … Read more
At Carolyn Kershaw and Darlene Musso’s first visit to Dana-Farber in July, Irene Ghobrial, MD, greeted them with some unexpected news. “We walked in and she said, ‘Did you know you two are famous in our lab?’” Kershaw recounts. Their local renown stems from their participation in the PROMISE study at Dana-Farber’s Center for the Prevention of Progression (CPOP), which … Read more
Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations — newly diagnosed, transplant eligible patients, and individuals whose disease has progressed following several lines of therapy. In one trial, the phase 2 GRIFFIN study showed … Read more
One bout of cancer is enough to contend with, but since 2014 Mary Johnson has had to cope with four different cancers and related conditions. Despite these tests of her physical and emotional strength, Johnson is doing well today after treatment at Dana-Farber. “Coming to Dana-Farber gave me confidence because they supported me, and I … Read more
Five years into his treatment for multiple myeloma, Mark Young was attending a Dana-Farber conference to learn about the latest research in the disease when his oncologist — Paul Richardson, MD, clinical program leader and director of clinical research at the Institute’s Jerome Lipper Multiple Myeloma Center — came running up with some timely news. … Read more
Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of currently available therapies, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. A clinical trial found that 26.2 percent of such patients responded with significant shrinkage … Read more
As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper … Read more
A study by Dana-Farber scientists and an international team of researchers could lead to better treatments for patients with smoldering multiple myeloma, a condition that often precedes myeloma.
大多数复发性癌症患者的确诊年龄往往在50岁以上。然而，在过去的几十年里，50岁以下的成年人确诊多种癌症的比率有所上升；这包括：乳腺癌（breast）、结直肠癌(colorectal)、子宫内膜癌（endometrial）、食管癌（esophageal）、胆管癌（bile duct）、胆囊癌（gallbladder）、头颈癌（head and neck）、肾癌（kidney）、肝癌（liver）、胰腺癌（pancreatic）、前列腺癌（prostate）、胃癌（stomach）、甲状腺癌（thyroid）和多发性骨髓瘤（multiple myeloma）。
2017年，Kelly Lamphere女士患有多发性骨髓瘤（multiple myeloma），且对疗法不起反应。骨骼中的癌症让她的双腿受限，她只能借助轮椅和拐杖行动。今天，正是因为CAR T-细胞疗法，Lamphere女士的病情得到有效控制，她还可以不借助拐杖再次行走。